Drug trial aims to halt silent attack on transplanted kidneys
NCT ID NCT02113891
Summary
This study aimed to see if a drug called eculizumab could stop a hidden type of kidney transplant rejection from causing permanent damage. It planned to treat sensitized patients who showed early signs of this rejection on a biopsy but had stable kidney function. The goal was to prevent the rejection from progressing and harming the transplanted kidney long-term.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SUBCLINICAL ACUTE ANTIBODY-MEDIATED REJECTION IN KIDNEY TRANSPLANTATION are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.